Page last updated: 2024-11-13

pyrazolopyridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pyrazolopyridine: act as competitive antagonists of brain adenosine A1 receptors [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID21643653
SCHEMBL ID10290
MeSH IDM0303742

Synonyms (26)

Synonym
1h-pyrazolo[4,3-b]pyridine
272-52-6
FT-0651102
AKOS006280755
pyrazolopyridine
272-51-5
A15441
pyrazolo[4,3-b]pyridine
AKOS016003571
2h-pyrazolo[4,3-b]pyridine
PS-4751
AM20051026
PB32568
SCHEMBL10290
AMFYRKOUWBAGHV-UHFFFAOYSA-N
SY008431
mfcd08234560
J-504739
Z2236735376
1h-pyrazolo[4,3-b]pyridine, aldrichcpr
CS-W003469
F18246
BCP26437
DTXSID10949931
EN300-103560
1h-pyrazolo[4 pound not3-b]pyridine

Research Excerpts

Overview

Pyrazolopyridine 20a is a potent and selective PDE4 inhibitor. It inhibits LPS induced TNF-alpha production from isolated human peripheral blood mononuclear cells.

ExcerptReferenceRelevance
"Pyrazolopyridine is a result of fusion of pyrazole and pyridine rings."( Pyrazolopyridine: An efficient pharmacophore in recent drug design and development.
Atukuri, D, 2022
)
2.89
"Pyrazolopyridine 20a was found to be a potent and selective PDE4 inhibitor which also inhibits LPS induced TNF-alpha production from isolated human peripheral blood mononuclear cells and has an encouraging rat PK profile suitable for oral dosing."( Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors.
Angell, TD; Ballantine, SP; Cook, CM; Cooper, AW; Dawson, J; Delves, CJ; Hamblin, JN; Jones, PS; Lindvall, M; Lucas, FS; Mitchell, CJ; Neu, MY; Ranshaw, LE; Solanke, YE; Somers, DO; Wiseman, JO, 2008
)
2.51

Bioavailability

ExcerptReferenceRelevance
" Compound 49 also displayed excellent selectivity over a wide panel of MMPs as well as excellent oral bioavailability (F%>90%) in rat n-in-1 PK studies."( Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE): discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1' substituents.
Anand, R; Christ, DD; Covington, MB; Duan, JJ; Liu, RQ; Lu, Z; Newton, RC; Ott, GR; Qian, M; Trzaskos, J; Vaddi, K, 2008
)
0.54
"UR-13756 is a potent and selective p38 mitogen-activated protein kinase (MAPK) inhibitor, reported to have good bioavailability and pharmacokinetic properties and, thus, is of potential use in the treatment of accelerated aging in Werner syndrome."( Synthesis of the highly selective p38 MAPK inhibitor UR-13756 for possible therapeutic use in Werner syndrome.
Bagley, MC; Davis, T; Kipling, D; Rokicki, MJ; Widdowson, CS, 2010
)
0.36
"Low intrinsic solubility leading to poor oral bioavailability is a common challenge in drug discovery that can often be overcome by formulation strategies, however, it remains a potential limitation that can pose challenges for early risk assessment and represent a significant obstacle to drug development."( Assessing the risk of drug crystallization in vivo.
Brodie, T; Carman, J; DiPiero, J; Drexler, D; Gemzik, B; Hageman, M; Hanumegowda, U; Hynes, J; Janovitz, E; Megill, J; Pan, D; Ruepp, S; Santella, J; Su, CC; White, R; Wu, Y,
)
0.13

Dosage Studied

ExcerptRelevanceReference
" The main finding in this study was minimal granulomatous inflammation in the duodenum, associated with the presence of birefringent crystals at the highest dosage of 100 mg/kg/day."( Assessing the risk of drug crystallization in vivo.
Brodie, T; Carman, J; DiPiero, J; Drexler, D; Gemzik, B; Hageman, M; Hanumegowda, U; Hynes, J; Janovitz, E; Megill, J; Pan, D; Ruepp, S; Santella, J; Su, CC; White, R; Wu, Y,
)
0.13
" However, dosing for 2 weeks was required for crystals to grow to a clearly detectable size."( Assessing the risk of drug crystallization in vivo.
Brodie, T; Carman, J; DiPiero, J; Drexler, D; Gemzik, B; Hageman, M; Hanumegowda, U; Hynes, J; Janovitz, E; Megill, J; Pan, D; Ruepp, S; Santella, J; Su, CC; White, R; Wu, Y,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (102)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (0.98)18.2507
2000's27 (26.47)29.6817
2010's67 (65.69)24.3611
2020's7 (6.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.98 (24.57)
Research Supply Index4.65 (2.92)
Research Growth Index6.59 (4.65)
Search Engine Demand Index42.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews6 (5.77%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other98 (94.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]